Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

PHASE3CompletedINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite)
Interventions
BIOLOGICAL

EN3835

Collagenase clostridium histolyticum

BIOLOGICAL

Placebo

Placebo

Trial Locations (26)

10022

Endo Clinical Trial Site #21, New York

10065

Endo Clinical Trial Site #19, New York

10075

Endo Clinical Trial Site #20, New York

10549

Endo Clinical Trial Site #18, Mount Kisco

22911

Endo Clinical Trial Site #26, Charlottesville

30078

Endo Clinical Trial Site #10, Snellville

33185

Endo Clinical Trial Site #9, Miami

33486

Endo Clinical Trial Site #7, Boca Raton

33770

Endo Clinical Trial Site #8, Largo

45249

Endo Clinical Trial Site #22, Cincinnati

55432

Endo Clinical Trial Site #15, Fridley

60654

Endo Clinical Trial Site #11, Chicago

63090

Endo Clinical Trial Site #16, Washington

68144

Endo Clinical Trial Site #17, Omaha

70115

Endo Clinical Trial Site #12, New Orleans

77056

Endo Clinical Trial Site #23, Houston

77497

Endo Clinical Trial Site #25, Sugar Land

78660

Endo Clinical Trial Site #24, Pflugerville

85258

Endo Clinical Trial Site #1, Scottsdale

90025

Endo Clinical Trial Site #4, Los Angeles

90806

Endo Clinical Trial Site #3, Long Beach

92024

Endo Clinical Trial Site #2, Encinitas

92056

Endo Clinical Trial Site #5, Oceanside

92121

Endo Clinical Trial Site #6, San Diego

02467

Endo Clinical Trial Site #13, Chestnut Hill

02169

Endo Clinical Trial Site #14, Quincy

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY